Importance Accurate diagnosis of pediatric patients with complicated neurological problems demands a well-coordinated combination of robust genetic analytic capability and delicate clinical evaluation. It should be tested whether this challenge can be augmented by whole exome sequencing (WES).
Introduction
The inherent complexity of brain developmental processes inevitably leads to patients with diverse neurological problems that frequently challenge conventional diagnostic criteria. Despite recent improvements in methodologies for understanding genetic pathogenesis mechanisms, diagnosis of neurological disorders affecting children are frequently hampered by rarity and overlapping clinical features, which makes it difficult for clinicians to readily recognize the disease entity for proper treatment 1 . A genome-wide survey revealed that such gene-to-phenotype relationships still remain elusive for about half of human genes 2 . Due to the immense complexity of central nervous system development and the clinical observation that a large fraction of rare and undefined disease patients display neurological features 3, 4 , it is reasonable to infer that pediatric neurologic patients are an impending target for the genome-wide genetic study.
Indeed, large-scale systematic efforts have been conducted at regional or national scales [5] [6] [7] [8] to facilitate diagnosis and discovery of novel disease pathophysiology. As many rare neurologic disorders in children follow Mendelian inheritance, disease-causing variant discovery by trio-based wholeexome sequencing (WES) has been the most robust methodology, yielding an instant diagnosis rate of 25-41% 1, 3, 4, 6, 8 .
Importantly, the medical system in Korea provides a unique opportunity to conduct a systematic survey of rare disorders at a large scale. With a nationwide referral system toward a handful of major tertiary clinical institutions, Seoul National University Children's Hospital (SNUCH) covers a large portion of the 51-million population, allowing for consistent evaluation and treatment of the patient cohort. For example, we recently reported genetic analyses of large patient cohorts of Duchenne muscular dystrophy (n = 507) and Rett-like syndrome without MECP2 mutations (n = 34) 9, 10 . Therefore, our study represents the largest of its kind conducted at a single clinic, with emphasis on the careful integration of clinical and genetic analyses.
Here we analyzed a cohort of 352 patients with various neurodevelopmental disorders using WES, experiencing a long undiagnosed period, and visiting multiple tertiary hospitals. We characterized the genotypephenotype relationships of patients whose molecular defects were identified, and explored the potential association of genes with no previous disease associations. Notable case vignettes are introduced to further highlight the clinical utility of WES. Overall, we describe the establishment of a system that achieved an efficient integration of advanced genetic techniques in clinical diagnosis processes to maximize benefits for pediatric patients and their families in Korea.
Methods

Subjects
This study was approved by the Seoul National University Hospital Institutional 
Whole Exome Sequencing
WES was performed at Theragen Etex Bio Institute (Suwon, Korea) following the standard protocol and the data were analyzed as described previously 10 .
Depending on the genetic analysis result, each patient was categorized as one of the following: category 1: known disease-causing genes were found; category 2: causative gene for other diseases were found; category 3: potentially pathogenic gene, but without prior disease association, was found; category 4: no disease-causing candidates were found; and category 5: known pathogenic copy number variation (CNV) was found.
Our variant assessment procedures were as follows: firstly, patientspecific CNVs were checked and samples with CNVs were classified as category 5. Then, patient-specific nucleotide variants such as de novo, compound heterozygous, and rare homozygous variants were selected by comparing against parents and prioritized based on the inheritance pattern ( Figure 1A ). In correlating the patient's symptoms with genetic variants, if patients carried a known pathogenic variant in OMIM or ClinVar, they were categorized as category 1 or 2, depending on similarity with reported and observed symptoms. For previously unreported variants, if they were never seen in normal individuals (Exome Aggregation Consortium (ExAC) 11 , 1000
Genomes Project 12 , Korean Variant Archive (KOVA) 13 and in-house variants) and were evolutionarily well-conserved at the amino acid level, they were categorized as potentially pathogenic. For CNV calling, the normalized coverage depths of each captured intervals were compared to the depths from related individuals.
Human Brain Transcriptome Data
The BrainSpan transcriptome database (http://www.brainspan.org) has been used to build developing human brain networks 14 . BrainSpan data from eight post-conceptual weeks to 40 years of age were analyzed. A total of 385 samples were used for the analysis after combining the multiplicates by taking mean values. Probes with TPM (transcripts per kilobase million) > 5 in at least one sample were used, yielding 23,943 probes as "brain-expressed transcripts".
Brain Transcriptome Network Analysis
Using the above brain-expressed transcripts, we created eight known gene coexpression networks by selecting genes that are highly correlated to our 109 known genes (Pearson's correlation coefficient > 0.7) from each developmental period (eFigure 2A in the Supplement). Then, we asked whether our novel genes can be successfully integrated into the known gene coexpression network. We randomly selected 45 genes (equal to the number of novel genes) in brainexpressed transcripts and counted how many edges they formed with the known genes. The 10 5 random gene selections were performed and the number of edges with a known gene was used to construct a distribution. The number of edges from our observed novel genes was evaluated against the random distributions. P-values were calculated using z-score, assuming normal distrubutions.
Results
WES analyses yielded a diagnostic success rate of 44.0%
The symptoms of the patients were mostly of pediatric onset (mean 1.4 years of age), harbored neurodevelopmental problems, and patients were soon referred to tertiary hospitals (mean 1.8 years of age). The majority of the patients 16 . They did not display skeletal problems, but showed blue sclera 17 . Adding this group yielded an instant diagnostic rate of 44.0% ("known genes"; eTable 2 in the Supplement).
Finally, 13.4% of the cohort (47 patients, 45 genes) harbored variants that are highly likely to be pathogenic but their disease associations are elusive ("novel genes"), yielding a "suggestive" diagnostic yield of 57.4% ( Figure 1B) . Overall, 58.6% of the variants are of de novo origin, and 22.9% are loss-of-function (LoF) to the gene (eFigures 5, 6 in the Supplement).
Novel genes display potential enrichment in neuronal differentiation
We assessed if our 45 novel genes indeed posed a neurologic disease-causing function. Firstly, the novel genes displayed significant enrichment in gene Next, we evaluated if our novel genes as a group displayed a strong correlation in expression with known disease-associated genes during brain development by simulating our novel gene set against the Allen Brain Atlas data (Materials and Methods). After 10 5 permutations, we found that the observed novel gene involvement was significantly stronger compared to the randomly 
Notable vignettes
WES-based diagnoses of 352 patients with neuro-developmental problems generated cases that were clinically meaningful for a number of reasons ( Figure   3 , Table 2 ).
ST3GAL5 case: genetic elucidation of a case of compound symptoms 18
Two female siblings presented with a Rett syndrome-like phenotype, such as psychomotor retardation/regression, delayed speech, hand stereotypies with a loss of purposeful hand movements, and choreoathetosis. Genetic tests of
MECP2/CDKL5/FOXG1 and chromosomal microarray found no plausible
candidates. GM3 synthase deficiency with ST3GAL5 compound heterozygous variants was diagnosed through WES, which was confirmed by liquid chromatography-mass spectrometry analysis 18, 19 . WES ended three years of an undiagnosed period and broadened the phenotypic spectrum of this rare neurometabolic disorder. SLC2A1 case: a case where an effective treatment was given A 16-year-old boy from an otherwise a healthy family displayed an abnormal gait from around eight years of age that later developed into falls with dystonia, notably in the lower extremities, which was provoked mainly by exercise or stress (Video 1). His motor development was delayed, although he had normal head circumference and cognition. WES revealed a de novo LoF variant in SLC2A1, encoding a glucose transporter (GLUT1) 22 (Figure 3E-G) . We also retrospectively noticed that he had developed episodes of staring spells from an age of four years, suggesting absence seizures, which disappeared after three years of antiepileptic medication. Cerebrospinal fluid analysis confirmed a low glucose level (37 mg/dL, 36% of serum glucose, normal range > 40%). Based on this observation, a ketogenic diet was applied and completely changed the quality of his life, with a resulting near-absence of dystonia (Video 2).
DYNC1H1 case: a case of evolving symptoms
RAB11B case: a case of newly identified disease through international data sharing 23
A 2-year-old boy was referred for evaluation of global developmental delay. He showed microcephaly and severe cognitive impairment with epilepsy but without evidence of regression. Notably, abnormal acanthotic skin lesions progressed from the face to the whole body. We identified a de novo variant in RAB11B and submitted this to GeneMatcher 24 . Soon, four cases with a similar neurodevelopmental phenotype were matched and we demonstrated that this gene causes intellectual disability and a distinctive brain phenotype 23 . 
Discussion
Our study demonstrated the clinical utility of WES in children with various and complex neurodevelopmental disorders. We identified genetic causes and sometimes corrected misdiagnoses to end the long journeys to diagnoses. We also found medically actionable cases where it was possible to offer the appropriate treatment options and a drug repositioning strategy ( Table 2 ). As such, WES facilitates enhanced clinical care, genetic counseling and a reduction of the psychosocial stress and medical costs for patients and their families.
Consistent with the previous studies, we were able to diagnose about one third of the patients (Figure 1 ). Our approach allowed for an expanding phenotypic spectrum of known genes ( . Furthermore, we observed differential diagnostic ratios when the cohort was subdivided into several major symptoms ( Figure 2 ). Data sharing programs such as GeneMatcher have proven to be pivotal when assessing these novel variants 10, 24 . The matching program allowed us to collect more patients of similar genotype and phenotype, and also provided evidence revealing whether the candidates are more likely to be true or not (eTable 3 in the Supplement).
Still, 42.6% of the cases (150/352) remained undiagnosed after our WES effort, suggesting a substantial opportunity for further improvement (Figure 1 ). Along this line, a systematic re-analysis effort with additional bioinformatics pipelines increased the diagnostic rate by 4.2% 25 . Also, searching for functional non-coding variants through whole genome sequencing (WGS) and evaluating multiple rare functional variants that may increase disease predisposition might be beneficial 26 , although a recent meta-analysis study claims only a minimal improvement in the diagnostic yield by WGS presumably due to our limited understanding of noncoding variant functions 27 .
An alternative approach would be to cross-link genome data with transcriptome data, to identify functional cryptic variants that directly influence expression of critical genes 28 , although preparing patient-derived tissues still remains a practical challenge.
Nevertheless, we highlight the clinical challenges that were posed by an evolving phenotype over time in growing children and how this can be overcome ( Figure 3A-D) , which facilitates identification of treatable or actionable cases ( Figure 3E-G) . Our patient cohort also included a successful drug repositioning case for a rare neurogenetic disease 29 ( Table 2 ). All of these cases are expected to increase as more genotype-phenotype relationships are discovered and more drugs become available. The unique Korean medical system leads to the concentration of clinically challenging patients into a few tertiary clinics, although patients still frequently experience unnecessary referrals and repeated tests. This study demonstrates that applying WES and subsequent in-depth analysis provides clinical and practical benefits to patients and their families.
Our study presented a genetic analysis of 352 Korean pediatric patients with unexplained neurodevelopmental problems, revealing various known and novel genetic etiologies. We provided rationales to aggressively extend our system to a wider ranges of undiagnosed rare disease patients in countries with centralized healthcare like Korea. Meanwhile, we also improved genome data generation and analytic methods. Through a careful integration of detailed phenotyping, genetic analysis and data sharing, we demonstrate how this approach allowed for more precise diagnosis and personalized patient care.
Finally, we reported on the successful establishment of such processes in Korea for patients with various undiagnosed neurodevelopmental disorders. the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
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